Stock Market News
Syncona pleased with 'strong' returns at year-end
Syncona issued its final results for the year ended 31 March on Thursday, reporting "strong" returns and a net asset value increase, with positive performance across the company.
The London-listed firm said net assets at year end were £1.06bn, or 158.9p per share, making for a total return of 18.7%.
It reported a 57.2% return from its life science portfolio, driven by financing events in Nightstar and Autolus and positive progress in Blue Earth.
Fund investments were valued at £465.1m, generating a return of 7.5% and providing a deep pool of capital which supported the deployment of £125.2m into new and follow-on life science investments.
The board declared a dividend of 2.3p, in line with that paid in 2017, alongside a charitable donation of £4.75m.
"This year we have seen our differentiated strategy continuing to deliver positive performance across the business, with strong NAV progression," said Syncona chief executive officer Martin Murphy.
"Our ability to create, invest in, and build global leaders in life science is underpinned by our evergreen funding base which enables us to take a flexible approach with control over how we manage our portfolio."
Murphy said Syncona's partnership approach had driven "strong" financial and operational progress in the year, delivering decent value progression across the portfolio.
He explained that Nightstar, Autolus and Freeline all commenced clinical trials, with Nightstar completing an initial public offering on Nasdaq four years after Syncona founded the company.
"Our established business, Blue Earth, continued to deliver strong sales and became the first Syncona founded company to reach profitability during the period," he said.
"This year Syncona also greatly strengthened its leadership position in gene therapy, including the establishment of two new companies, and we now have one of the broadest, high-quality, coordinated gene therapy platforms globally.
"We look forward to helping these businesses fulfil their potential in delivering truly transformational treatment to patients, and value to our shareholders."
The London-listed firm said net assets at year end were £1.06bn, or 158.9p per share, making for a total return of 18.7%.
It reported a 57.2% return from its life science portfolio, driven by financing events in Nightstar and Autolus and positive progress in Blue Earth.
Fund investments were valued at £465.1m, generating a return of 7.5% and providing a deep pool of capital which supported the deployment of £125.2m into new and follow-on life science investments.
The board declared a dividend of 2.3p, in line with that paid in 2017, alongside a charitable donation of £4.75m.
"This year we have seen our differentiated strategy continuing to deliver positive performance across the business, with strong NAV progression," said Syncona chief executive officer Martin Murphy.
"Our ability to create, invest in, and build global leaders in life science is underpinned by our evergreen funding base which enables us to take a flexible approach with control over how we manage our portfolio."
Murphy said Syncona's partnership approach had driven "strong" financial and operational progress in the year, delivering decent value progression across the portfolio.
He explained that Nightstar, Autolus and Freeline all commenced clinical trials, with Nightstar completing an initial public offering on Nasdaq four years after Syncona founded the company.
"Our established business, Blue Earth, continued to deliver strong sales and became the first Syncona founded company to reach profitability during the period," he said.
"This year Syncona also greatly strengthened its leadership position in gene therapy, including the establishment of two new companies, and we now have one of the broadest, high-quality, coordinated gene therapy platforms globally.
"We look forward to helping these businesses fulfil their potential in delivering truly transformational treatment to patients, and value to our shareholders."
Related share prices |
---|
Syncona Limited NPV (SYNC) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price